Theriva Biologics, Inc.
As of Oct 22, 2026, Theriva Biologics is in Stage 4, the downtrend phase, now in week 11 (since Aug 11, 2026). It closed at $0.19, 53.7% below its 52-week high and below its 200-day average, which is rising.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is TOVX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TOVX among Biotechnology302nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …302 | TOVX | Stage 4 · wk 11 | 30 | −17.4% |
Theriva Biologics: quick answers
What stage is Theriva Biologics in?
As of Oct 22, 2026, Theriva Biologics (TOVX) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 11, 2026 and is in week 11. What the four stages mean
Is Theriva Biologics in an uptrend?
No. Theriva Biologics is in a Stage 4 downtrend. It trades 21.0% below its 200-day average, which is rising.
How far is Theriva Biologics from its 52-week high?
Theriva Biologics closed at $0.19 on Oct 22, 2026, 53.7% below its 52-week high of $0.41. Its 52-week low is $0.18.
How has Theriva Biologics performed over the past year?
As of Oct 22, 2026, Theriva Biologics is down 36.7% over the past year and down 26.9% so far in 2026.
Which sector and industry is Theriva Biologics in?
Theriva Biologics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.